Champions Oncology, Inc.

Equities

CSBR

US15870P3073

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
5.02 USD -0.79% Intraday chart for Champions Oncology, Inc. -0.79% -10.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. CI
Craig-Hallum Downgrades Champions Oncology to Hold From Buy MT
Champions Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Transcript : Champions Oncology, Inc., Q3 2024 Earnings Call, Mar 12, 2024
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. CI
Craig Hallum Trims Champions Oncology Price target to $9 From $10, Maintains Buy Rating MT
Transcript : Champions Oncology, Inc., Q2 2024 Earnings Call, Dec 12, 2023
Champions Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
MORNING BID AMERICAS-Disinflation station RE
North American Morning Briefing : Traders Eye -2- DJ
Champions Oncology, Inc. Appoints Brady Davis as President CI
Roth MKM Adjusts Price Target on Champions Oncology to $7.50 From $9, Maintains Buy Rating MT
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. CI
Transcript : Champions Oncology, Inc., Q1 2024 Earnings Call, Sep 13, 2023
Champions Oncology, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
Champions Oncology Enters Multiyear Deal With BioVolume to Better Evaluate Cancer Studies MT
Champions Oncology, Inc. Announces Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies CI
Transcript : Champions Oncology, Inc., Q4 2023 Earnings Call, Jul 24, 2023
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. CI
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023 CI
Champions Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended April 30, 2023 CI
Champions Oncology Forms Therapeutic Discovery Platform Unit Corellia AI MT
Champions Oncology, Inc. announces an Equity Buyback for $5 million worth of its shares. CI
Champions Oncology, Inc. authorizes a Buyback Plan. CI
Benchmark Company Downgrades Champions Oncology to Hold From Speculative Buy MT
Chart Champions Oncology, Inc.
More charts
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.02 USD
Average target price
6 USD
Spread / Average Target
+19.52%
Consensus
  1. Stock Market
  2. Equities
  3. CSBR Stock
  4. News Champions Oncology, Inc.
  5. Craig-Hallum Downgrades Champions Oncology to Hold From Buy